Overview

Honored with Frost & Sullivan’s Global Product Leadership Award for leading the critical-care immunotherapy segment in blood purification, CytoSorbents Corporation is currently distributing its EU-approved CytoSorb cytokine adsorber in 75 countries around the world. CytoSorb® is helping to treat life-threatening conditions in the intensive care unit and cardiac surgery. One major application is the reduction of cytokine storm, with the goal of reducing severe inflammation and serious complications such as organ failure—the leading cause of death in the ICU today, while improving patient outcomes and reducing overall costs of critical care. Another newer application is the reduction of antithrombotic agents, often called “blood thinners,” during open heart surgery, with the goal of reducing unwanted perioperative bleeding.


Data Provided by Refinitiv.
Minimum 15 minutes delayed.

Press Release

07 Nov '24
PRINCETON, N.J. , Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported unaudited financial and operating results for the third...

Upcoming Events

More events are coming soon.

Featured Reports